Inogen, Inc. (NASDAQ:INGN) Shares Purchased by State Street Corp

State Street Corp lifted its position in Inogen, Inc. (NASDAQ:INGN) by 2.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 511,018 shares of the medical technology company’s stock after acquiring an additional 14,054 shares during the quarter. State Street Corp’s holdings in Inogen were worth $4,957,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in INGN. Divisadero Street Capital Management LP raised its stake in Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after acquiring an additional 2,046,766 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after purchasing an additional 132,287 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Inogen during the 2nd quarter valued at approximately $651,000. Finally, Monaco Asset Management SAM bought a new position in Inogen during the 2nd quarter worth $610,000. 89.94% of the stock is currently owned by institutional investors.

Inogen Trading Down 0.2 %

Shares of NASDAQ INGN opened at $8.58 on Monday. Inogen, Inc. has a 12-month low of $5.08 and a 12-month high of $13.33. The company has a market cap of $204.38 million, a PE ratio of -3.81 and a beta of 1.02. The stock has a 50 day simple moving average of $9.38 and a 200-day simple moving average of $9.74.

Analysts Set New Price Targets

A number of research firms have issued reports on INGN. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research note on Friday, November 8th. StockNews.com cut shares of Inogen from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.